Physician profile
James Turner
NPI 1073022042
$2,766.72
in general payments reported to CMS, 2019-2025
29 companies · $19.27 in 2025
The $19.27 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $916 · 2022: $843 · 2023: $650 · 2024: $338 · 2025: $19.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,006.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $946.07 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $488.19 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $180.71 | 2021-2022 | |
| Lilly USA, LLC | $145.92 | 2021-2024 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $105.50 | 2021-2024 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $102.82 | 2021-2024 | Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $97.15 | 2021-2024 | |
| Novo Nordisk INC | $92.85 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $71.19 | 2022 | |
| Mylan Specialty L.P. | $65.17 | 2021-2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $62.84 | 2021 | |
| Ironshore Pharmaceuticals INC. | $37.92 | 2023 | Jornay Pm |
| Biohaven Pharmaceuticals, INC. | $34.32 | 2021 | |
| Almatica Pharma LLC | $30.39 | 2024 | Loreev Xr |
| Pfizer INC. | $28.75 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $27.90 | 2024 | Fanapt |
| Supernus Pharmaceuticals, INC. | $27.31 | 2021-2022 | |
| Redhill Biopharma INC. | $27.28 | 2021 | |
| Idorsia Pharmaceuticals US INC | $22.89 | 2024 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.80 | 2022 | |
| Antares Pharma, INC. | $22.14 | 2022 | |
| Nevro Corp. | $21.30 | 2022 | |
| Tris Pharma INC | $20.03 | 2024 | Dyanavel Xr |
| Astellas Pharma US INC | $18.35 | 2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $15.22 | 2022 | |
| Shield Therapeutics INC | $13.48 | 2024 | |
| Janssen Pharmaceuticals, INC | $13.03 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.87 | 2021 | |
| Avanir Pharmaceuticals, INC. | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.